A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia

Depression is the most common psychiatric disorder among the elderly and in old age may interact with emotional and cognitive functioning. Depression in old age has been shown to be associated with degenerative changes in the brain. It is, therefore, important that in this patient population antidep...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of geriatric psychiatry 2000-04, Vol.15 (4), p.295-305
Hauptverfasser: Karlsson, Ingvar, Godderis, Jan, Augusto De Mendonça Lima, Carlos, Nygaard, Harald, Simányi, Margarete, Taal, Maarja, Eglin, Mirjam
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 305
container_issue 4
container_start_page 295
container_title International journal of geriatric psychiatry
container_volume 15
creator Karlsson, Ingvar
Godderis, Jan
Augusto De Mendonça Lima, Carlos
Nygaard, Harald
Simányi, Margarete
Taal, Maarja
Eglin, Mirjam
description Depression is the most common psychiatric disorder among the elderly and in old age may interact with emotional and cognitive functioning. Depression in old age has been shown to be associated with degenerative changes in the brain. It is, therefore, important that in this patient population antidepressants with a favourable tolerability profile, such as the selective serotonin reuptake inhibitors (SSRIs), are examined for both antidepressant efficacy and effect on cognitive function and emotional impairment. This randomised, double‐blind study compared the efficacy and tolerability of citalopram and mianserin in 336 elderly, depressed patients with or without dementia. Patients received either citalopram 20–40 mg/day or mianserin 30–60 mg/day for 12 weeks. The treatments were equivalent with respect to change in Montgomery–Åsberg Depression Rating Scale (MADRS) total score; patients in both treatment groups responded well. Patients with dementia showed a smaller decrease in total MADRS score than patients without dementia. Both treatments were well tolerated with a relatively low incidence of adverse events. Fatigue and somnolence were more frequent with mianserin, while insomnia was more frequent with citalopram. Overall, this study showed that the two treatments were equivalent in efficacy, and that citalopram is an effective, well‐tolerated and non‐sedative treatment for elderly depressed patients with or without dementia. Copyright © 2000 John Wiley & Sons, Ltd.
doi_str_mv 10.1002/(SICI)1099-1166(200004)15:4<295::AID-GPS105>3.0.CO;2-C
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_21100373</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21100373</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4365-8a82e79fe8625edd9b74da80d33e885612bc407e0920dcd16b6705093c64187f3</originalsourceid><addsrcrecordid>eNqFkeuK1DAUx4so7rj6CpJPsgt2zKVt2lUWxuqOA4Mjjrdvh7Q5ZaNtU5MO6zyU72jGDougYAgEkv8lnF8UXTI6Z5TyZ2fbVbk6Z7QoYsay7IzTsJJzll4kL3iRXlwsVq_i5bsto-mlmNN5uXnO4_JONLu13I1mNM_TOOOCnkQPvP8aEoqC5fejE0ZlJiXPZ9HPBXGq17YzHvVTou2uajGuWtNrUttuUM542xPbkPEaCTaNqVW9J8FCvGpw3B-eajOq1g5OdUcPajJa0hnVe3SmJ2Fjq9G1-1CBg0Mf2sigRoP96MmNGa-Jdb9PuxuDsZ0CbPCoEYOnC0KjHkb3GtV6fHQ8T6OPV68_lG_i9Wa5KhfruE5Elsa5yjnKosE84ylqXVQy0SqnWggMI8kYr-qESqQFp7rWLKsySVNaiDpLWC4bcRo9mXIHZ7_v0I8Q5lNj26oe7c4DZwGSkCIIP03C2lnvHTYwONMptwdG4QAS4AASDlTgQAUmkMBSSCCABAggYQIJAiiUG-BQhuDHxx_sqg71H7ETuSD4MgluTIv7v2r_0_rP0uNNiI6naONH_HEbrdw3yKSQKXx-u4ScXuXJy_dbWItftYrLGg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21100373</pqid></control><display><type>article</type><title>A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Karlsson, Ingvar ; Godderis, Jan ; Augusto De Mendonça Lima, Carlos ; Nygaard, Harald ; Simányi, Margarete ; Taal, Maarja ; Eglin, Mirjam</creator><creatorcontrib>Karlsson, Ingvar ; Godderis, Jan ; Augusto De Mendonça Lima, Carlos ; Nygaard, Harald ; Simányi, Margarete ; Taal, Maarja ; Eglin, Mirjam</creatorcontrib><description>Depression is the most common psychiatric disorder among the elderly and in old age may interact with emotional and cognitive functioning. Depression in old age has been shown to be associated with degenerative changes in the brain. It is, therefore, important that in this patient population antidepressants with a favourable tolerability profile, such as the selective serotonin reuptake inhibitors (SSRIs), are examined for both antidepressant efficacy and effect on cognitive function and emotional impairment. This randomised, double‐blind study compared the efficacy and tolerability of citalopram and mianserin in 336 elderly, depressed patients with or without dementia. Patients received either citalopram 20–40 mg/day or mianserin 30–60 mg/day for 12 weeks. The treatments were equivalent with respect to change in Montgomery–Åsberg Depression Rating Scale (MADRS) total score; patients in both treatment groups responded well. Patients with dementia showed a smaller decrease in total MADRS score than patients without dementia. Both treatments were well tolerated with a relatively low incidence of adverse events. Fatigue and somnolence were more frequent with mianserin, while insomnia was more frequent with citalopram. Overall, this study showed that the two treatments were equivalent in efficacy, and that citalopram is an effective, well‐tolerated and non‐sedative treatment for elderly depressed patients with or without dementia. Copyright © 2000 John Wiley &amp; Sons, Ltd.</description><identifier>ISSN: 0885-6230</identifier><identifier>EISSN: 1099-1166</identifier><identifier>DOI: 10.1002/(SICI)1099-1166(200004)15:4&lt;295::AID-GPS105&gt;3.0.CO;2-C</identifier><identifier>PMID: 10767728</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Ltd</publisher><subject>Aged ; Aged, 80 and over ; Antidepressive Agents, Second-Generation - adverse effects ; Antidepressive Agents, Second-Generation - pharmacology ; Antidepressive Agents, Second-Generation - therapeutic use ; citalopram ; Citalopram - adverse effects ; Citalopram - pharmacology ; Citalopram - therapeutic use ; dementia ; Dementia - complications ; depression ; Depressive Disorder - complications ; Depressive Disorder - drug therapy ; Double-Blind Method ; elderly ; Europe ; Female ; Humans ; Male ; mianserin ; Mianserin - adverse effects ; Mianserin - pharmacology ; Mianserin - therapeutic use ; Psychiatric Status Rating Scales ; Severity of Illness Index ; Survival Analysis ; Treatment Outcome</subject><ispartof>International journal of geriatric psychiatry, 2000-04, Vol.15 (4), p.295-305</ispartof><rights>Copyright © 2000 John Wiley &amp; Sons, Ltd.</rights><rights>Copyright 2000 John Wiley &amp; Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4365-8a82e79fe8625edd9b74da80d33e885612bc407e0920dcd16b6705093c64187f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291099-1166%28200004%2915%3A4%3C295%3A%3AAID-GPS105%3E3.0.CO%3B2-C$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291099-1166%28200004%2915%3A4%3C295%3A%3AAID-GPS105%3E3.0.CO%3B2-C$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10767728$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karlsson, Ingvar</creatorcontrib><creatorcontrib>Godderis, Jan</creatorcontrib><creatorcontrib>Augusto De Mendonça Lima, Carlos</creatorcontrib><creatorcontrib>Nygaard, Harald</creatorcontrib><creatorcontrib>Simányi, Margarete</creatorcontrib><creatorcontrib>Taal, Maarja</creatorcontrib><creatorcontrib>Eglin, Mirjam</creatorcontrib><title>A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia</title><title>International journal of geriatric psychiatry</title><addtitle>Int. J. Geriat. Psychiatry</addtitle><description>Depression is the most common psychiatric disorder among the elderly and in old age may interact with emotional and cognitive functioning. Depression in old age has been shown to be associated with degenerative changes in the brain. It is, therefore, important that in this patient population antidepressants with a favourable tolerability profile, such as the selective serotonin reuptake inhibitors (SSRIs), are examined for both antidepressant efficacy and effect on cognitive function and emotional impairment. This randomised, double‐blind study compared the efficacy and tolerability of citalopram and mianserin in 336 elderly, depressed patients with or without dementia. Patients received either citalopram 20–40 mg/day or mianserin 30–60 mg/day for 12 weeks. The treatments were equivalent with respect to change in Montgomery–Åsberg Depression Rating Scale (MADRS) total score; patients in both treatment groups responded well. Patients with dementia showed a smaller decrease in total MADRS score than patients without dementia. Both treatments were well tolerated with a relatively low incidence of adverse events. Fatigue and somnolence were more frequent with mianserin, while insomnia was more frequent with citalopram. Overall, this study showed that the two treatments were equivalent in efficacy, and that citalopram is an effective, well‐tolerated and non‐sedative treatment for elderly depressed patients with or without dementia. Copyright © 2000 John Wiley &amp; Sons, Ltd.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antidepressive Agents, Second-Generation - adverse effects</subject><subject>Antidepressive Agents, Second-Generation - pharmacology</subject><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>citalopram</subject><subject>Citalopram - adverse effects</subject><subject>Citalopram - pharmacology</subject><subject>Citalopram - therapeutic use</subject><subject>dementia</subject><subject>Dementia - complications</subject><subject>depression</subject><subject>Depressive Disorder - complications</subject><subject>Depressive Disorder - drug therapy</subject><subject>Double-Blind Method</subject><subject>elderly</subject><subject>Europe</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>mianserin</subject><subject>Mianserin - adverse effects</subject><subject>Mianserin - pharmacology</subject><subject>Mianserin - therapeutic use</subject><subject>Psychiatric Status Rating Scales</subject><subject>Severity of Illness Index</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><issn>0885-6230</issn><issn>1099-1166</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkeuK1DAUx4so7rj6CpJPsgt2zKVt2lUWxuqOA4Mjjrdvh7Q5ZaNtU5MO6zyU72jGDougYAgEkv8lnF8UXTI6Z5TyZ2fbVbk6Z7QoYsay7IzTsJJzll4kL3iRXlwsVq_i5bsto-mlmNN5uXnO4_JONLu13I1mNM_TOOOCnkQPvP8aEoqC5fejE0ZlJiXPZ9HPBXGq17YzHvVTou2uajGuWtNrUttuUM542xPbkPEaCTaNqVW9J8FCvGpw3B-eajOq1g5OdUcPajJa0hnVe3SmJ2Fjq9G1-1CBg0Mf2sigRoP96MmNGa-Jdb9PuxuDsZ0CbPCoEYOnC0KjHkb3GtV6fHQ8T6OPV68_lG_i9Wa5KhfruE5Elsa5yjnKosE84ylqXVQy0SqnWggMI8kYr-qESqQFp7rWLKsySVNaiDpLWC4bcRo9mXIHZ7_v0I8Q5lNj26oe7c4DZwGSkCIIP03C2lnvHTYwONMptwdG4QAS4AASDlTgQAUmkMBSSCCABAggYQIJAiiUG-BQhuDHxx_sqg71H7ETuSD4MgluTIv7v2r_0_rP0uNNiI6naONH_HEbrdw3yKSQKXx-u4ScXuXJy_dbWItftYrLGg</recordid><startdate>200004</startdate><enddate>200004</enddate><creator>Karlsson, Ingvar</creator><creator>Godderis, Jan</creator><creator>Augusto De Mendonça Lima, Carlos</creator><creator>Nygaard, Harald</creator><creator>Simányi, Margarete</creator><creator>Taal, Maarja</creator><creator>Eglin, Mirjam</creator><general>John Wiley &amp; Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>200004</creationdate><title>A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia</title><author>Karlsson, Ingvar ; Godderis, Jan ; Augusto De Mendonça Lima, Carlos ; Nygaard, Harald ; Simányi, Margarete ; Taal, Maarja ; Eglin, Mirjam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4365-8a82e79fe8625edd9b74da80d33e885612bc407e0920dcd16b6705093c64187f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antidepressive Agents, Second-Generation - adverse effects</topic><topic>Antidepressive Agents, Second-Generation - pharmacology</topic><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>citalopram</topic><topic>Citalopram - adverse effects</topic><topic>Citalopram - pharmacology</topic><topic>Citalopram - therapeutic use</topic><topic>dementia</topic><topic>Dementia - complications</topic><topic>depression</topic><topic>Depressive Disorder - complications</topic><topic>Depressive Disorder - drug therapy</topic><topic>Double-Blind Method</topic><topic>elderly</topic><topic>Europe</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>mianserin</topic><topic>Mianserin - adverse effects</topic><topic>Mianserin - pharmacology</topic><topic>Mianserin - therapeutic use</topic><topic>Psychiatric Status Rating Scales</topic><topic>Severity of Illness Index</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karlsson, Ingvar</creatorcontrib><creatorcontrib>Godderis, Jan</creatorcontrib><creatorcontrib>Augusto De Mendonça Lima, Carlos</creatorcontrib><creatorcontrib>Nygaard, Harald</creatorcontrib><creatorcontrib>Simányi, Margarete</creatorcontrib><creatorcontrib>Taal, Maarja</creatorcontrib><creatorcontrib>Eglin, Mirjam</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>International journal of geriatric psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karlsson, Ingvar</au><au>Godderis, Jan</au><au>Augusto De Mendonça Lima, Carlos</au><au>Nygaard, Harald</au><au>Simányi, Margarete</au><au>Taal, Maarja</au><au>Eglin, Mirjam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia</atitle><jtitle>International journal of geriatric psychiatry</jtitle><addtitle>Int. J. Geriat. Psychiatry</addtitle><date>2000-04</date><risdate>2000</risdate><volume>15</volume><issue>4</issue><spage>295</spage><epage>305</epage><pages>295-305</pages><issn>0885-6230</issn><eissn>1099-1166</eissn><abstract>Depression is the most common psychiatric disorder among the elderly and in old age may interact with emotional and cognitive functioning. Depression in old age has been shown to be associated with degenerative changes in the brain. It is, therefore, important that in this patient population antidepressants with a favourable tolerability profile, such as the selective serotonin reuptake inhibitors (SSRIs), are examined for both antidepressant efficacy and effect on cognitive function and emotional impairment. This randomised, double‐blind study compared the efficacy and tolerability of citalopram and mianserin in 336 elderly, depressed patients with or without dementia. Patients received either citalopram 20–40 mg/day or mianserin 30–60 mg/day for 12 weeks. The treatments were equivalent with respect to change in Montgomery–Åsberg Depression Rating Scale (MADRS) total score; patients in both treatment groups responded well. Patients with dementia showed a smaller decrease in total MADRS score than patients without dementia. Both treatments were well tolerated with a relatively low incidence of adverse events. Fatigue and somnolence were more frequent with mianserin, while insomnia was more frequent with citalopram. Overall, this study showed that the two treatments were equivalent in efficacy, and that citalopram is an effective, well‐tolerated and non‐sedative treatment for elderly depressed patients with or without dementia. Copyright © 2000 John Wiley &amp; Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Ltd</pub><pmid>10767728</pmid><doi>10.1002/(SICI)1099-1166(200004)15:4&lt;295::AID-GPS105&gt;3.0.CO;2-C</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0885-6230
ispartof International journal of geriatric psychiatry, 2000-04, Vol.15 (4), p.295-305
issn 0885-6230
1099-1166
language eng
recordid cdi_proquest_miscellaneous_21100373
source MEDLINE; Wiley Online Library All Journals
subjects Aged
Aged, 80 and over
Antidepressive Agents, Second-Generation - adverse effects
Antidepressive Agents, Second-Generation - pharmacology
Antidepressive Agents, Second-Generation - therapeutic use
citalopram
Citalopram - adverse effects
Citalopram - pharmacology
Citalopram - therapeutic use
dementia
Dementia - complications
depression
Depressive Disorder - complications
Depressive Disorder - drug therapy
Double-Blind Method
elderly
Europe
Female
Humans
Male
mianserin
Mianserin - adverse effects
Mianserin - pharmacology
Mianserin - therapeutic use
Psychiatric Status Rating Scales
Severity of Illness Index
Survival Analysis
Treatment Outcome
title A randomised, double-blind comparison of the efficacy and safety of citalopram compared to mianserin in elderly, depressed patients with or without mild to moderate dementia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A25%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20randomised,%20double-blind%20comparison%20of%20the%20efficacy%20and%20safety%20of%20citalopram%20compared%20to%20mianserin%20in%20elderly,%20depressed%20patients%20with%20or%20without%20mild%20to%20moderate%20dementia&rft.jtitle=International%20journal%20of%20geriatric%20psychiatry&rft.au=Karlsson,%20Ingvar&rft.date=2000-04&rft.volume=15&rft.issue=4&rft.spage=295&rft.epage=305&rft.pages=295-305&rft.issn=0885-6230&rft.eissn=1099-1166&rft_id=info:doi/10.1002/(SICI)1099-1166(200004)15:4%3C295::AID-GPS105%3E3.0.CO;2-C&rft_dat=%3Cproquest_cross%3E21100373%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21100373&rft_id=info:pmid/10767728&rfr_iscdi=true